Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3CNS 3Lymphoid 2Gynecologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Fibrolamellar hepatocellular carcinoma 1Adenoma, Islet Cell 1

Interventions

Gemcitabine 218Fluorouracil 142Oxaliplatin 132Capecitabine 122pembrolizumab 113Irinotecan 110Leucovorin 104Bevacizumab 98Nivolumab 80Cisplatin 80130-nm albumin-bound paclitaxel 80Cetuximab 79Radiotherapy 78Albumin-Bound Paclitaxel 59Sorafenib 56Paclitaxel 53Cyclophosphamide 50Carboplatin 47Magnetic Resonance Spectroscopy 44Specimen Handling 39Docetaxel 37Taxes 36fludarabine 34Radiation 34durvalumab 33Ipilimumab 33Erlotinib Hydrochloride 33Biopsy 33Radiosurgery 27Folfox protocol 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × sapanisertib × Gastrointestinal × Clear all
NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
83 enrolled 21 charts
GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡